Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration

Diabetes

Volumn 48, Issue 6, 2000, Pages 1308-1315

  He, Cijiang ^a   Sabol, Jennifer ^a   Mitsuhashi, Tomoko ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE;

ANIMAL EXPERIMENT; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; FEMALE; FOOD PROCESSING; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RAT; TOXICOKINETICS; URINARY EXCRETION;

ANIMALS; DIET; ENZYME INHIBITORS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; KIDNEY; METABOLIC CLEARANCE RATE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0345711536     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.6.1308     Document Type: Article

References (38)

1. Grandhee SK, Monnier VM: Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 266:11649-11653, 1991
2. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW: Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34:3702-3709, 1995
3. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138-151, 1994
4. Brownlee M, Cerami A, Vlassara H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 4:437-451, 1988
5. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR: Reactive glycosylation end-products in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
6. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 91:9441-9445, 1994
7. Mitsuhashi T, Li YM, Fishbane S, Vlassara H: Depletion of reactive advanced glycation endproducts diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 100:847-854, 1997
8. Bucala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26:875-888, 1995
9. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91:11704-11708, 1994
10. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91:9436-9440, 1995
11. Vlassara H, Fuh H, Donnelly T, Cybulsky M: Advanced glycation endproducts promote adhesion molecule (VCAMf-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1:447-456, 1995
12. Makita Z, Radoff S, Rayfield EJ, Yang Z, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
13. O'Brien J: Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr 28:211-248, 1989
14. Lee T, Kimiagar M, Pintauro SJ, Chichester CO: Physiological and safety aspects of Maillard browning of foods. Prog Food Nutr Sci 5:243-256, 1981
15. Finot PA, Magnenat E: Metabolic transit of early and advanced Maillard products. Prog Food Nutr Sci 5:193-207, 1981
16. Sgarbieri VC, Amaya J, Tanaka M, Chichester CO: Nutritional consequences of the Maillard reaction. Amino acid availability from fructose-leucine and fructose-tryptophan in the rat. J Nutr 103:657-663, 1973
17. Koschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): a potential risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474-6479, 1997
18. Bradford M: A rapid and sensitive assay for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-250, 1976
19. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
20. Mitsuhashi T, Vlassara H, Li YM: Standardization of immunological measurement for advanced glycation endproducts (AGEs) using normal human serum (NHS). J Immunol Methods 207:79-88, 1996
21. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1:634-646, 1995
22. Li YM, Mitsuhashi T, Wojciehowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H: Molecular identity and cellular distribution of advanced glycation endproduct receptors. Proc Natl Acad Sci U S A 93:11047-11052, 1996
23. Giardino I, Edelstein D, Brownlee M: Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 94:110-117, 1994
24. Li YM, Tan AX, Vlassara H: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nature Med 1:1057-1061, 1995
25. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T: b2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
26. Gibaldi M, Perrier D: Pharmacokinetics. New York, Marcel Dekker, 1982
27. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258:651-653, 1992
28. Gugliucci A, Bendayan M: Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39:149-160, 1996
29. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H: Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 174:515-524, 1991
30. Vander Jagt DL, Hunsaker LA, Deck LM, Chamblee BB, Royer RE: Ketoaldehyde detoxification enzymes and protection against the Maillard reaction. Maillard Reactions in Chemistry, Food, and Health. Proceedings of the Fifth International Symposium on the Maillard Reaction, University of Minnesota, 1993, p. 314-318
31. Thornalley PJ: The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269:1-11, 1990
32. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M: Isolation and characterization of two binding proteins for advanced glycosylation endproducts from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987-14997, 1992
33. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
34. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
35. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88:11555-11558, 1991
36. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A 88:6107-6111, 1991
37. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47-52, 1992
38. Giardino I, Fard AK, Hatchell DL, Brownlee M: Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47:1114-1120, 1998